Utocare

Solifenacin succinate

Symptomatic treatment of urge incontinence &/or increased urinary frequency & urgency in patients w/ overactive bladder syndrome.

Adult, including the elderly 5 mg once daily, may be increased to 10 mg once daily if needed. Patient w/ severe renal impairment (CrCl ≤30 mL/min) Max: 5 mg once daily. Patient w/ moderate hepatic impairment (Child-Pugh score 7-9) Max: 5 mg once daily. Concomitant w/ potent CYP3A4 inhibitor Max: 5 mg once daily.

May be taken with or without food: Swallow whole w/ liqd.

Hypersensitivity. Patients w/ urinary retention, severe GI condition (including toxic megacolon), myasthenia gravis or narrow-angle glaucoma & in patients at risk for these conditions. Patients undergoing haemodialysis; patients w/ severe hepatic impairment; patients w/ severe renal impairment or moderate hepatic impairment & who are on treatment w/ a potent CYP3A4 inhibitor eg, ketoconazole.

Assess other causes of frequent urination (heart failure or renal disease) before treatment. Start an appropriate antibacterial therapy if UTI is present. Caution in patients w/ clinically significant bladder outflow obstruction at risk of urinary retention; GI obstructive disorders; risk of decreased GI motility; severe renal impairment (CrCl ≤30 mL/min); moderate hepatic impairment (Child-Pugh score 7-9); concomitant use of a potent CYP3A4 inhibitor eg, ketoconazole; hiatus hernia/gastro-oesophageal reflux &/or who are concurrently taking medicinal products (eg, bisphosphonates) that can cause or exacerbate oesophagitis; autonomic neuropathy. Reports of QT prolongation & Torsade de Pointes in patients w/ risk factors eg, pre-existing long QT syndrome & hypokalaemia; angioedema w/ airway obstruction; anaphylactic reactions. Safety & efficacy have not been established in patients w/ neurogenic cause for detrusor overactivity. Patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. Do not use in childn.

Drugs for Bladder & Prostate Disorders

G04BD08 - solifenacin ; Belongs to the class of urinary antispasmodics.

P₁S₁S₃